All In Biotech

Drug Trial Radar · NCT06842199

Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Oral ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 383 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

383

Planned (sponsor's estimate)

Start

Mar 20, 2025

Primary completion

May 2026

Study completion Feb 2027

Sponsor

Sponsor type
Industry
First posted
Feb 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.

Conditions

  • Plaque Psoriasis Patients

Interventions

  • ICP-488 TabletsDrug

    Eligible patients will receive ICP-488 orally as per the protocol

  • ICP-488 PlaceboDrug

    Eligible patients will receive ICP-488 Placebo orally as per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects who achieve a score of clear (0) or almost clear (1) with an improvement of at least 2 points from baseline on the static Physician's Global Assessment (sPGA) at week 16Time frame: week 16
  2. Percentage of subjects who achieved a PASI 75 response (a reduction of minimum 75% from baseline in PASI score) at Week 16Time frame: Week 16

Locations

46 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Completed

  • The Second Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China · Completed

  • Beijing Chao-Yang Hospital,Capital Medical University

    Beijing, Beijing Municipality, China · Completed

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Completed

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Completed

  • Beijing Tongren Hospital,CMU

    Beijing, Beijing Municipality, China · Completed

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Completed

  • Chongqing Traditional Chinese Medicine Hospital

    Chongqing, Chongqing Municipality, China · Completed

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Completed

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Completed

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Completed

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Completed

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China · Completed

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Completed

  • Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China · Completed

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Completed

  • The 2nd Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Completed

  • The Second Affiliated Hospital of Henan University of Science and technology

    Luoyang, Henan, China · Completed

  • Nanyang Central Hospital

    Nanyang, Henan, China · Completed

  • Sanmenxia Central Hospital

    Sanmenxia, Henan, China · Completed

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Completed

  • Jingzhou Central Hospital

    Jingzhou, Hubei, China · Completed

  • Wuhan Hospital Of Traditional Chinese and Western Medicine (Wuhan No.1 Hospital)

    Wuhan, Hubei, China · Completed

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Completed

  • The Second Xiangya Hospital of Central South

    Changsha, Hunan, China · Completed

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, China · Completed

  • The First People's Hospital of Lianyungang

    Lianyungang, Jiangsu, China · Completed

  • Hospital for skin diseases,Institute of dermatology chinese academy of medical sciences,peking union medical college

    Nanjing, Jiangsu, China · Completed

  • First Affiliated Hospital of Gannan Medical University

    Ganzhou, Jiangxi, China · Completed

  • Dermatology Hospital of Jiangxi Province

    Nanchang, Jiangxi, China · Completed

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Completed

  • Northeast International Hospital

    Shenyang, Liaoning, China · Completed

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Completed

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Completed

  • Shanghai Skin Disease Hospital skin Disease of tongji University

    Shanghai, Shanghai Municipality, China · Completed

  • Taiyuan Central Hospital

    Taiyuan, Shanxi, China · Completed

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China · Recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China · Completed

  • Chengdu Second People's Hospital

    Chengdu, Sichuan, China · Completed

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Completed

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.